

IFOSFAMIDE AND ITS MAIN METABOLITES IN CHILDREN DURING THE FIRST 4 DAYS OF A CONTINUOUS INFUSION (Meeting abstract).

Sub-category:

Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Category:

Developmental Therapeutics

Meeting:

1998 ASCO Annual Meeting

Abstract No:

846

Author(s):

B Gourmel, N Delepine, S Denis, B Bousquet, G Delepine

Abstract:

Forty cures of Ifosfamide (If.) were administered to 14 children, aged 2 to 19 years. The dose regimen was 3g/m²/day during 4 to 7 days. Auto-induction of the parent compound has been previously described in such administration conditions. A new gas-chromatography method, allowing simultaneous determination of If. and its main metabolites, either inactive 2 and 3 dechloroethyl If. (2dlf.,3dlf.) or active 4 hydroxy If.(4OHlf.), enabled us to estimate the real impact of this process on drug metabolism and metabolite production. Data were estimated between the 1st and the 4th days. To compare inter-patient results, data were expressed in grams of If. infused per day. The table summarizes the mean values and the SD of the concentrations ([Mu]g/ml) and of the areas under curve ([Mu]g*h/ml). Despite large inter-individual variations, similar curve features were noted for each patient. Concerning the If conc. it is clear that a continuous decrease (49.7%) was observed related to induction whereas 2dlf. and 3dlf. reached max conc. on day 2 and then decreased slightly. At the same time 4OHlf increased (29.7%). Concerning A.U.C, If. value was max at 24--48h and then decreased (16.8%). Metabolite data at this time still remained constant or decreasing for 2dlf. Maximum 4OHlf production was reached at 48--72h. These data suggest that, despite induction of the parent compound, inactive metabolism seemed to be saturable from day 2 even when the active one increased slightly. Nevertheless, as 4OHlf is the sole component able to enter the cell, its production could be greater than observed.

► Associated Presentation(s):

No items found.

► Other Abstracts in this Sub-Category:

1. RALOXIFENE REDUCES THE RISK OF BREAST CANCER AND MAY DECREASE THE RISK OF ENDOMETRIAL CANCER IN POST-MENOPAUSAL WOMEN. TWO-YEAR FINDINGS FROM THE MULTIPLE OUTCOMES OF RALOXIFENE EVALUATION (MORE TRIAL (Meeting abstract).

Meeting: 1998 ASCO Annual Meeting Abstract No: 3 First Author: SR Cummings
Category: Developmental Therapeutics - Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

2. THE ROLE OF GLUCURONIDATION IN 7-ETHYL-10-HYDROXYCAMPTOTHECIN (SN-38) RESISTANCE (Meeting abstract).

Meeting: 1998 ASCO Annual Meeting Abstract No: 713 First Author: T Takahashi
Category: Developmental Therapeutics - Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

3. BILIRUBIN (BIL) AND SN-38 METABOLISM: PHARMACODYNAMICS OF CPT-11 TOXICITY (Meeting abstract).

Meeting: [1998 ASCO Annual Meeting](#) Abstract No: 714 First Author: [E Wasserman](#)
Category: [Developmental Therapeutics - Developmental Therapeutics - Clinical Pharmacology and Immunotherapy](#)

[More...](#)

► Abstracts by B Gourmel:

1. Adjustment of DOSE of ifosfamide (If.) in children after the first treatment session.

Meeting: [2008 ASCO Annual Meeting](#) Abstract No: 10038 First Author: [B. Gourmel III](#)
Category: [Pediatric Oncology - Pediatric Solid Tumors](#)

2. Ifosfamide given once every other week: A clinical and pharmacological study.

Meeting: [2007 ASCO Annual Meeting](#) Abstract No: 13008 First Author: [W. Cacheux](#)
Category: [Developmental Therapeutics - Clinical Pharmacology and Immunotherapy - Pharmacology/Pharmacokinetics](#)

3. Pharmacokinetic evaluation of the Auto-Inductive effect of a single dose of Ifosfamide administered each 15 days

Meeting: [2005 ASCO Annual Meeting](#) Abstract No: 2111 First Author: [b. gourmel](#)
Category: [Developmental Therapeutics - Clinical Pharmacology and Immunotherapy - Pharmacology/Pharmacokinetics](#)

[More...](#)

► Presentations by B Gourmel:

1. Adjustment of DOSE of ifosfamide (If.) in children after the first treatment session.

Meeting: [2008 ASCO Annual Meeting](#)
Presenter: [Bernard Gourmel, MD](#)
Session: [Pediatric Cancer \(General Poster Session\)](#)

2. Variation of the metabolite index of ifosfamide metabolites during a 5-day continuous injection in children

Meeting: [2003 ASCO Annual Meeting](#)
Presenter: [Bernard Gourmel, MD](#)
Session: [Pediatric Oncology: Leukemia and Developmental Therapeutics \(General Poster Session\)](#)

3. Comparaison Of The Induction Effect Of Ifosfamide In Children And Adult Population During Continuous Infusion. Consequences On Its Metabolites

Meeting: [2001 ASCO Annual Meeting](#)
Presenter: [Bernard Gourmel](#)
Session: [Clinical Pharmacology \(General Poster Session\)](#)

[More...](#)

► Educational Book Manuscripts by B Gourmel:

No items found.

© Copyright 2006 American Society of Clinical Oncology All rights reserved worldwide.